이노큐어테라퓨틱스
1 known investors
Korean biotech developing targeted protein degradation drugs using PROTAC and AUTAC-type degrader platforms.
Also known as ㈜이노큐어테라퓨틱스 · InnoCure Therapeutics · 이노큐어
Investors · 1
Company profile
researched Aug 2026InnoCure Therapeutics (㈜이노큐어테라퓨틱스) is a South Korean drug discovery company founded on 23 January 2018 and headquartered at #205, 2F, 331 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, where it also operates its bio lab and R&D center. Its business is registered as pharmaceutical development within the physical, chemical and biological research and development sector, and it is classified as a small and medium-sized enterprise and certified venture company. Yoo Hye-dong serves as representative director (CEO).
The company works on targeted protein degradation (TPD) technologies, specifically PROTACs and AUPTACs, to create drugs against pathogenic proteins that have traditionally been considered undruggable by conventional small molecules, with a stated focus on rare and hard-to-treat diseases and indications with limited treatment options. Disclosed research directions include degraders targeting BRD4-NUT for NUT midline carcinoma (NMC), c-MET-targeting degraders and small-molecule c-MET inhibitors, new CRBN E3 ligase binders and PROTACs, an ELCBIL technology, and a MILPROTAC concept. The company states it has secured proprietary platform technology to strengthen patentability as well as core technology for oral formulation, and it pursues open innovation and multidisciplinary collaboration for novel drug development and global expansion.
Founding story
InnoCure Therapeutics was established in 2018 with a registered incorporation date of 23 January 2018, receiving seed support from the Korea Credit Guarantee Fund in its founding year.
Business model
Preclinical-stage drug discovery: the company develops its own degrader programs and platform intellectual property, and undertakes joint PROTAC development with corporate partners while drawing on Korean government R&D funding programs.
No revenue model disclosed in the available material; funding to date has come from equity investment and government R&D programs.
Traction
Selected in December 2023 for the Korea Drug Development Fund's 2023 third-round candidate-stage program for its BRD4-NUT-targeting NUT midline carcinoma degrader, with two years of support toward final preclinical candidate selection; a second KDDF award covers preclinical development of a c-MET targeting degrader. The company has built a multi-jurisdiction patent portfolio and has run several joint development programs with corporate partners.
Latest developments
In February 2026 the company announced its 8th annual general meeting for 16 March 2026, covering 2025 financial statements, employee stock option grants, and director and auditor remuneration limits. On 30 July 2026 it announced an extraordinary general meeting for 11 August 2026 to approve a capital increase, together with a new share issuance notice for 47,214 redeemable convertible preferred shares at 21,180 won per share (par value 500 won), totaling 999,992,520 won, with subscription on 12 August 2026 and payment due 13 August 2026 via third-party allocation.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned among Korean targeted protein degradation biotechs, developing degrader candidates for undruggable targets and rare cancers; recognized as an 'Aby Unicorn' program company and a certified venture company.
The company cites proprietary platform technology developed to strengthen patent position and core technology enabling oral formulation of degraders, applied to targets such as BRD4-NUT for which no specific therapy exists.
Technology
Targeted protein degradation platforms based on PROTACs and AUPTACs, including proprietary CRBN E3 ligase binders, small-molecule warheads, ELCBIL and MILPROTAC technologies, and core technology intended to enable oral dosing. Programs include BRD4-NUT and c-MET/BET degraders and c-MET small-molecule inhibitors.
Go-to-market
Partnering-driven: joint PROTAC development agreements with unnamed bio and industrial companies, participation in global pharmaceutical business partnering activity, and use of open innovation to reach global markets.
Patients with rare and intractable diseases including NUT midline carcinoma, addressed through pharmaceutical partners and licensees.
Geography
Headquarters, bio lab and R&D center in Pangyo, Seongnam-si, Gyeonggi-do, South Korea; earlier facilities included an R&D center in Pangyo and a chemical R&D center in Gwanggyo. Patent filings extend to Korea, PCT, the United States, the EU, Japan and China.
History
Founded in 2018, with seed backing from the Korea Credit Guarantee Fund that year. In 2019 the company opened an R&D center in Pangyo, received investment via the TIPS program and VC, completed pre-A funding, and expanded its Pangyo R&D facilities. In 2020 it added a new chemical R&D center in Gwanggyo, completed Series A funding, was certified as a venture company by KIBO, and won the Digital Innovation Grand Award. In 2021 it filed IP for a new CRBN E3 binder and PROTAC (Korea/PCT) and small-molecule warhead IP, began joint PROTAC development with an unnamed 'S' bio company, and was awarded the Start-up Leap Forward Package by the Ministry of SMEs and Startups. In 2022 it registered ELCBIL IP in Korea and filed applications covering c-MET inhibitors, c-MET/BET-degrading PROTACs, MILPROTAC, and a CRBN E3 binder/PROTAC in the USA and EU, plus joint development with 'L' bio and 'I' companies. In 2023 it filed CRBN E3 binder/PROTAC IP in Japan and China, relocated its HQ and R&D center within Pangyo, received second and third KDDF awards, and completed bridge funding.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 15
launches, deals, and filingsAnnounced issuance of 47,214 redeemable convertible preferred shares at 21,180 won per share (par value 500 won) for a total of 999,992,520 won via third-party allocation, subject to an extraordinary general meeting on 11 August 2026; subscription 12 August 2026 and payment due 13 August 2026.
Notice of the 8th annual general meeting set for 16 March 2026, with agenda items covering FY2025 financial statements, employee stock option grants, and director and auditor remuneration limits.
Announced on 4 December 2023 that its BRD4-NUT-targeting degrader for NUT midline carcinoma was selected as a 2023 third-round KDDF candidate-stage project and that an agreement was signed; support runs for two years toward final preclinical candidate selection.
Opened a new R&D center in Pangyo and later expanded facilities at the site.
Received investment through the Korean TIPS program and venture capital, and completed pre-A funding.
Corporate registration records list an establishment date of 23 January 2018.
Received seed support from the Korea Credit Guarantee Fund (KCGF) in its founding year.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- (주)이노큐어테라퓨틱스innocurethera.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 이노큐어테라퓨틱스 do?
- Korean biotech developing targeted protein degradation drugs using PROTAC and AUTAC-type degrader platforms.
- Who are 이노큐어테라퓨틱스's investors?
- 이노큐어테라퓨틱스's investors include Laguna Investment.